About Action Pharma
a biopharmaceutical company founded in 2000 and located in Denmark The company's main strategy is to bring drug candidates rapidly from pre-clinical development into clinical trials for subsequent partnering.The goal is to bring one drug candidate into clinical development per year and currently two lead candidates are in clinical development. The company plan to seek partners for late clinical development and commercialisation of the company's drug candidates after successful development in phase I or II by partnering with major biotech and pharmaceutical companies.
Missing: Action Pharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Action Pharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Action Pharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Action Pharma is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Latest Action Pharma News
Jun 27, 2013
Action Pharma Frequently Asked Questions (FAQ)
When was Action Pharma founded?
Action Pharma was founded in 2000.
What is Action Pharma's latest funding round?
Action Pharma's latest funding round is Series B.
How much did Action Pharma raise?
Action Pharma raised a total of $19.95M.
Who are the investors of Action Pharma?
Investors of Action Pharma include Global Life Science Ventures, Innovations Kapital, Inventure, SLS Invest and Sunstone Capital.
Who are Action Pharma's competitors?
Competitors of Action Pharma include ChemoCentryx, Oligomerix, Innate Pharma, ForSight VISION4, CMC Biologics and 15 more.
Compare Action Pharma to Competitors
Angel Biotechnology Holdings PLC (AIM: ABH) is a world class, contract biomanufacturing company offering process development services and pre-GMP and cGMP manufacturing to support biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines. nnAngel is managed by a team that has more than 100 years' combined experience in pharmaceutical and biopharmaceutical manufacture, gained in companies such as Glaxo and Serologicals Inc. nnAngel operates out of Pentlands Science Park, near Edinburgh.
Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.
BioVascular Inc. is a privately held biotechnology company that develops drugs and devices for the control of intimal hyperplasia associated with vascular procedures and control of risk factors associated with cardiovascular morbidity and mortality. BioVascular's lead product, saratin, is a polypeptide produced by recombinant means in yeast. This product was licensed from Merck, KGaA in 2005. BioVascular began human clinical trials of saratin for hemodialysis graft access in late 2006 and will begin human trials in the treatment of peripheral artery grafts in early 2007. BioVascular's second product utilizes a mechanism for reduction of a recently defined cardiovascular risk factor. This product will enter human studies in mid 2007.
Cerecin is a biopharmaceutical company with a drug for Alzheimer's in late-stage clinical testing. Cerecin's pipeline consists of therapeutic drugs and medical foods for neurodegenerative diseases such as Alzheimer's, Parkinson's, and Age-Associated Memory Impairment. The company was founded in 2001 and is based in Singapore.
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.
Argenes, Inc. is a Japanese bio-venture established in April 2004 focusing primarily on the development of biopharmaceuticals and molecular targeting therapeutics, including anti-rheumatoid arthritis (RA), and anti-osteoarthritis. Currently, the company's most innovatory prospective candidate for the treatment of RA is the drug anti-Fas mAb ARG098. The company operate preclinical and clinical studies as well as manufacturer pharmaceuticals through managing of CRO and CMO. At Argenes, Inc. the company continually seek to expand globally through creating alliances and through licensing out development rights and marketing rights.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.